Ventrus shares soar on PhIII pain data; Maxygen earns $30M payment from Bayer; Big Pharma backs university collab;

 @FierceBiotech: FDA panel gave Gilead's key HIV drug Quad the OK on Friday. More | Follow @FierceBiotech

 @RyanMFierce: Category: Things CROs are good at. Wrong answer: Patient recruitment for clinical trials. Article | Follow @RyanMFierce

 @JohnCFierce: Come back from vacation to find lorcaserin looking pretty good for an approval. But how much could Arena really make from it? | Follow @JohnCFierce

> Shares of Ventrus Biosciences ($VTUS) shot up 19% this morning after the developer announced positive results from a late-stage study of its experimental medication VEN 307, which is being developed to treat pain associated with anal fissures. Story

> San Mateo, CA-based Maxygen ($MAXY) has earned a final, $30 million contingency payment from Bayer for a hemophilia treatment. Bayer initially paid $90 million upfront in 2008 for rights to the therapy. Release

> Fierce 15 winner F-star, an antibody developer, has undergone a management makeover. The biotech says it named Dr. John Haurum as the new CEO and will concentrate all of its R&D work in Cambridge in the U.K. Release

> Six top pharma companies, including Pfizer ($PFE), Merck Serono and GlaxoSmithKline ($GSK), have committed £14.4 million in support for a long-term collaboration between academic investors and pharma scientists. Report

> In the wake of a positive expert panel vote, Eisai has expanded its marketing deal with Arena on the obesity drug lorcaserin. Story

Pharma News

 @FiercePharma: Merck Serono workers threaten to strike in opposition to Geneva HQ closure. Already, protestors have hit the streets. | Follow @FiercePharma

> Eisai broadens marketing deal for Arena's weight-loss drug. Story

> Sales-needy Takeda springs for emerging markets growth. Article

> Servier, founder face trial on Mediator charges. News

Medical Devices News

 @FierceMedDev: Medtronic's latest study attempts to convince you that CRT-Ds are a bargain. More | Follow @FierceMedDev

> Regentis grabs $10M Series C for cartilage regeneration implant trials. Article

> FDA panel wants higher standard for obesity-treating devices. Story

> D. Medical eyes world stage for insulin infusion device. More

> Consumer group wary of industry concessions in FDA user fee bill. Report

Biotech IT News

> Join a live Twitter chat with Medidata's Glen de Vries. More

> BioClinica chief touts Microsoft ties in Q1 report. News

> Boehringer, pharmas turn to social gaming for online outreach. Article

> Roche unit allies with genomics software group SoftGenetics. More

> NIH pumps $6M into DNA analysis for Alzheimer's plan. Item

And Finally… Sir Chris Evans has outlined some ambitious plans for Wales' new biotech venture fund. Companies can gain up to $16 million, says Evans. Story

 

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.